Tuuli Ranki, VP Preclinical development and IP (PhD, co-founder), has 14 years of experience in the development of genetically modified oncolytic adenoviruses for cancer immunotherapy. During her career, she has designed oncolytic adenoviruses and taken these through preclinical testing into clinical trials. Tuuli worked as a Director at Oncos Therapeutics and was responsible for the development of proprietary oncolytic adenovirus constructs as well as securing the company's intellectual property rights, where her work led to the successful patenting of products. Tuuli has gained in-depth knowledge of the cancer immunotherapy field through her parallel involvement in the analysis and interpretation of clinical trial samples, the results of which she has published. Tuuli earned her PhD in the Faculty of Medicine at the University of Helsinki, and her doctoral thesis concentrated on oncolytic adenoviruses in cancer treatment. Tuuli Ranki, VP Preclinical development and IP (PhD, co-founder), has 14 years of experience in the development of genetically modified oncolytic adenoviruses for cancer immunotherapy. During her career, she has designed oncolytic adenoviruses and taken these through preclinical testing into clinical trials. Tuuli worked as a Director at Oncos Therapeutics and was responsible for the development of proprietary oncolytic adenovirus constructs as well as securing the company's intellectual property rights, where her work led to the successful patenting of products. Tuuli has gained in-depth knowledge of the cancer immunotherapy field through her parallel involvement in the analysis and interpretation of clinical trial samples, the results of which she has published. Tuuli earned her PhD in the Faculty of Medicine at the University of Helsinki, and her doctoral thesis concentrated on oncolytic adenoviruses in cancer treatment.

Preclinical development